Pulmonary hypertension (PH) is a chronic, life-threatening condition involving high blood pressure in the arteries of the ...

Cibotercept is a fusion protein commercialized by Keros Therapeutics, with a leading Phase II program in Pulmonary Arterial Hypertension.

Use precise geolocation data and actively scan device characteristics for identification. This is done to store and access ...

Drivers could face £1,000 fines or even lose their driving licence if they do not declare one of 110 medical conditions, the DVLA has warned.

Detailed price information for Keros Therapeutics Inc (KROS-Q) from The Globe and Mail including charting and trades.